In the News

Cardio-Oncology in China – A New Frontier!

Admin • CCON • 12/15/2016

From the first Cardio-Oncology workshop in June 2016 to a national meeting in November, the First Affiliated Hospital of Dalian Medical University in partnership with Peony Solutions, accelerates growth of... Read more »

Read More...

ACC Cardio-Oncology Course

Admin • CCON • 10/28/2016

Register today and save for the inaugural Advancing Cardiovascular Care of the Oncology Patient course.   As the patient population with cancer and cancer survivors who have significant cardiovascular risk factors and cardiovascular... Read more »

Read More...

Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy

Admin • CCON • 7/31/2016

Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy Canadian Journal of Cardiology, July 2016, Volume 32, Issue 7, Pages 831–841 Read Article Here

Read More...

Cardiac Surveillance Guidelines for Trastuzumab-Containing Therapy in Early-Stage Breast Cancer: Getting to the Heart of the Matter

Admin • CCON • 2/2/2016

Chau T. Dang, Anthony F. Yu, Lee W. Jones, Jennifer Liu, Richard M. Steingart, Daniel F. Argolo, Larry Norton and Clifford A. Hudis Journal of Clinical Oncology Published online before print. February 1, 2016, doi:10.1200/JCO.2015.64.5515JCO February 1, 2016 JCO645515 Read Article

Read More...

Stem Cell Theranostics and CapellaBio Announce Cardio-Oncology Collaboration and Discovery of a Novel Class of Cardioprotective Drug Therapies

Admin • CCON • 12/16/2015

REDWOOD CITY, Calif. and PALO ALTO, Calif., Dec. 16, 2015 /PRNewswire/ — Stem Cell Theranostics (SCT) and CapellaBio announced today that they have established a cardio-oncology collaboration to discover novel drug therapies to prevent... Read more »

Read More...

Cardiac Meds Appear to Protect Heart From Herceptin Damage

Admin • CCON • 12/15/2015

SAN ANTONIO ― Breast cancer patients treated with trastuzumab (Herceptin, Genentech, Inc) had significantly lower risk for left ventricular (LV) dysfunction and consequent treatment interruptions when treated prophylactically with heart... Read more »

Read More...

KU hospital program promotes heart health for cancer patients

Admin • CCON • 12/14/2015

KANSAS CITY, Kan. —A program at the University of Kansas Hospital is now combining cardiology and oncology. Read More

Read More...

Mixed Results for Herceptin Cardiotoxicity Prevention

Admin • CCON • 12/10/2015

Neither a beta-blocker nor an angiotensin-converting enzyme (ACE) inhibitor, used as prophylaxis against trastuzumab’s (Herceptin) adverse cardiac effects, successfully prevented left ventricle remodelling in breast cancer patients in a randomized... Read more »

Read More...

Prophylactic Heart Failure Pharmacotherapy Is Safe and Effective in Patients With HER2-overexpressing Breast Cancer

Admin • CCON • 12/9/2015

SAN ANTONIO, TX—Results from the MANTICORE trial include prophylactic use of standard heart failure (HF) pharmacotherapy prevents trastuzumab-associated left ventricular ejection fraction (LVEF) and reduces treatment interruptions due to left... Read more »

Read More...

Can cancer itself damage the heart?

Admin • CCON • 12/3/2015

Research presented today at EuroEcho-Imaging 2015 raises the possibility that cancer itself may damage heart muscle irrespective of exposure to cancer drug therapies. Researchers from the UK’s first dedicated cardio-oncology... Read more »

Read More...